The simultaneous and efficient delivery of cisplatin and pooled siRNAs to ovarian cancer can allow for enhanced anticancer efficacy by blocking drug resistance pathways.
At a time when it is hard to raise new capital, the firm has decided to concentrate on anticancer therapies that, it hopes, are nearer to being commercial propositions than the stem-cell study is.